Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
COSMOS PharmaceuticalCSMYF 93 3-Year EBITDA Growth Rate is 11.40% as of Feb. 2026, which is 7% below its 10-year median of 12.20. GuruFocus rates CSMYF with a GF Score™ of 93/100 and a GF Value™ of $51.85 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 528 Healthcare Providers & Services companies, COSMOS Pharmaceutical ranks better than 51.89% on this metric.
During the past 12 months, COSMOS Pharmaceutical's average EBITDA Per Share Growth Rate was 7.00% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 11.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 7.00% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 7.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of COSMOS Pharmaceutical was 36.70% per year. The lowest was -9.30% per year. And the median was 12.20% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
COSMOS Pharmaceutical 3-Year EBITDA Growth Rate Related Terms
For the Pharmaceutical Retailers subindustry, COSMOS Pharmaceutical's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
COSMOS Pharmaceutical 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, COSMOS Pharmaceutical's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where COSMOS Pharmaceutical's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 11.40% mean?
COSMOS Pharmaceutical (CSMYF) has a 3-Year EBITDA Growth Rate of 11.40% as of Feb. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for COSMOS Pharmaceutical and its competitors. This is near median its historical median of 12.20. According to the industry distribution chart, COSMOS Pharmaceutical ranks #254 out of 528 companies in the Healthcare Providers & Services industry, placing it in the top 48.1%.
Is COSMOS Pharmaceutical's 3-Year EBITDA Growth Rate too high?
COSMOS Pharmaceutical's current 3-Year EBITDA Growth Rate of 11.40% is near median its 10-year median of 12.20. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 10.20. COSMOS Pharmaceutical's value of 11.40% is 11.8% above this industry median. Based on the distribution chart, COSMOS Pharmaceutical ranks #254 out of 528 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, COSMOS Pharmaceutical has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does COSMOS Pharmaceutical's 3-Year EBITDA Growth Rate compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, COSMOS Pharmaceutical ranks #254 out of 528 companies for 3-Year EBITDA Growth Rate. This puts COSMOS Pharmaceutical in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 10.20. COSMOS Pharmaceutical's value of 11.40% is 11.8% above this benchmark. While the company's 10-year median is 12.20 vs. the industry median of 10.20, COSMOS Pharmaceutical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.20, based on 528 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. COSMOS Pharmaceutical's current 3-Year EBITDA Growth Rate of 11.40% is 11.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for COSMOS Pharmaceutical and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. COSMOS Pharmaceutical's current 3-Year EBITDA Growth Rate is 11.40%, which is near median its own 10-year median of 12.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is COSMOS Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, COSMOS Pharmaceutical (CSMYF) is currently considered Modestly Undervalued. The stock's GF Value™ is $51.85, compared to a current price of $37.06 — trading 28.5% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 11.40%, which is near median its 10-year median of 12.20 and 11.8% above the Healthcare Providers & Services industry median of 10.20. COSMOS Pharmaceutical's overall GF Score™ is 93/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For COSMOS Pharmaceutical (CSMYF), the current 3-Year EBITDA Growth Rate is 11.40% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is COSMOS Pharmaceutical (CSMYF) Overvalued in 2026?
Based on GuruFocus' analysis, COSMOS Pharmaceutical stock appears to be undervalued.
The current stock price of $37.06 is trading 28.5% below its estimated GF Value™ of $51.85.
GuruFocus considers COSMOS Pharmaceutical to be Modestly Undervalued.
Key valuation signals for CSMYF:
3-Year EBITDA Growth Rate: 11.40% (near median its 10-year median of 12.20)
GF Value™: $51.85 vs. price of $37.06 (28.5% below fair value)
Industry Position: 11.8% above the Healthcare Providers & Services median (#254 of 528)
No single metric tells the full story. See the CSMYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
COSMOS Pharmaceutical Corp manages retail drugstores in Japan. The company emphasizes convenience regarding its product selection, which includes medical products, health and beauty aids, personal-care items, discount cosmetics, household items, food and beverages, greeting cards, seasonal merchandise, alcoholic beverages, tobacco, insect repellent, and miscellaneous everyday consumables. The majority of the company's revenue is derived from common grocery sales. It also operates a private grocery brand called ON 365.
93GF Score
Get the complete analysis for CSMYF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSMYF has been successfully added to your 
